7 results about "Pharmacogenetics" patented technology

The present invention relates to pharmacogenetics, more specifically to strategies involving biomarkers associated with the clinical response to a compound before or during treatment of a cartilage disorder, such as osteoarthritis. The present invention more particularly relates to the combination of JSW measurements and level of specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used in strategies such as patients' enrichment in clinical trials, patients' selection strategy before or during treatment or for adapting the treatment of a patient in the frame of treatments for cartilage disorder, such as osteoarthritis.

The present invention discloses a primer composition and its use in the preparation of a product for detecting SNP sites associated with the use of antipsychotic drugs. The present invention is directed to 18 SNP sites associated with the use of antipsychotic drugs, screened according to literature reports and the guidelines of the Clinical Pharmacogenetics Implementation Alliance, and obtains a set of primer compositions capable of sensitively and specifically detecting the 18 SNP sites, and constructs a corresponding kit using the primer composition. Using the primer composition or the kit of the present invention, the 18 SNP sites can be detected in combination with time-of-flight mass spectrometry, and the personalized use of antipsychotic drugs can be guided based on the SNP site detection results, thereby avoiding situations such as drug non-response and severe side effects, which is beneficial to the treatment of mental illnesses such as schizophrenia.

The invention relates to the technical field of biological science, and discloses application of a BLAWFS1-NAc neural circuit as a drug target in preparation of a drug for treating risk assessment abnormality. The BLAWFS1-NAc neural circuit is activated through optogenetics and pharmacogenetics, so that the behavior of risk assessment can be remarkably increased, and the abnormal risk assessment behavior of risk avoidance deficiency is improved.

An electronic data interface overlay for modifying existing formulary data is provided along with systems and methods for the same. The overlay comprises member-specific clinical data and causes automatic generation of code(s) indicating coverage denial upon querying of treatments of the existing formulary data associated with certain of the member-specific clinical data, such as pharmacogenetic (“PGx”) test results, of the data interface overlay. The formulary data includes alternative treatments which may be suggested and approved upon denial based on PGx test results. An electronic health record is automatically updated with the alternative treatment.

A computer-implemented method for determining pharmacogenetic star alleles from high-throughput sequencing data is described, comprising the following steps: providing a plurality of result files output by a plurality of different genotyping computer programs, each containing multiple result elements, where each result element includes at least one gene designation; performing, for each result element of the multiple result elements from each result file of the plurality of result files, a right-sided truncation of the allele designation that is as extensive as possible; and outputting the gene designation and a specific result diplotype. Furthermore, a computer-implemented method for determining rare genetic variants is also described. Finally, a device comprising a processor and memory for performing such methods is described.

We have identified panels of proxy single nucleotide polymorphisms (SNPs) that are highly predictive of particular HLA risk alleles, and concordant across multi-ethnic populations. Accordingly, methods are provided involving clinical DNA testing for HLA panel markers to assess risk for life-threatening adverse drug reactions associated with the human leucocyte antigen (HLA) alleles HLA-B*57:01, HLA-B*15:02, HLA-A*31:01 and HLA-B*58:01. Methods of treating a subject with a drug associated with an adverse drug reaction (ADR) are provided. Based on the assessed risk to a subject for developing an adverse drug reaction in response to a drug, appropriate administrations of the drug can be made. In some embodiments of the method, the drug is administered when there is a low assessed risk of ADR in the subject. Alternatively, when there is a high assessed risk of ADR in the subject, a reduced dosage of the drug, or no drug, can be administered.

Computer implemented systems and methods for adjudication of treatments and prescriptions for a patient are provided. The method may comprise receiving a request to approve a medical request for administering a treatment to a patient; accessing a database of genetic information to determine genetic information of the patient; comparing the genetic information of the patient against a database of pharmacogenetic information in view of the medical request; and providing a response to the medical request, the response including one or more of administering the treatment to the patient, or offering an alternate treatment for the patient.